FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023421823> ?p ?o ?g. }

• W2023421823 endingPage "81" @default.
• W2023421823 startingPage "72" @default.
• W2023421823 abstract "To compare the efficacy of oral liarozole, the first retinoic acid metabolism-blocking agent (RAMBA) to be developed as differentiation therapy for human solid tumors, with that of cyproterone acetate (CPA), an antiandrogen for the treatment of metastatic prostate cancer. Liarozole promotes differentiation of cancer cells by increasing the intratumoral levels of retinoic acid.A total of 321 patients with metastatic prostate cancer in relapse after first-line endocrine therapy entered a Phase III international multicenter study (recruitment from February 1992 to August 1994) comparing liarozole (300 mg two times daily) with CPA (100 mg two times daily).Accounting for differences in baseline prognostic factors, the adjusted hazard ratio for survival was 0.74 in favor of liarozole (P = 0.039), indicating a 26% lower risk of death than in patients treated with CPA. Median crude (unadjusted) survival time was the same in the liarozole group as in the CPA group (10.3 months). More patients showed a PSA response (at least 50% reduction in PSA from baseline) when treated with liarozole (20%) than with CPA (4%) (P < 0.001). Prostate-specific antigen (PSA) responders had a median survival benefit of 10 months over nonresponders, irrespective of treatment (hazard ratio 0.43; P = 0.0018). PSA response was apparent within 3 months in approximately 90% of patients who responded. Pain improved more in the liarozole group than in the CPA group (P = 0.03). PSA responders had lower median pain scores than nonresponders (1.7 versus 2.5) and better quality of life (median Functional Living Index-Cancer score 108 versus 98) at end point, ie, treatment discontinuation, as well as throughout the treatment period. Among the most frequently occurring adverse events in the liarozole group were dry skin (51% of patients), pruritus (25%), rash (16%), nail disorders (16%), and hair loss (15%). These adverse events were generally mild to moderate in severity and did not affect the overall quality of life score. There were no detectable effects of either treatment on vital signs such as blood pressure, heart rate, electrocardiogram, and body weight.Liarozole is superior to CPA in terms of PSA response, PSA progression, and survival, and is capable of maintaining patients' quality of life. The observed adverse events were mild to moderate in nature. These results show that liarozole is a possible treatment option after first-line endocrine therapy has failed." @default.
• W2023421823 created "2016-06-24" @default.
• W2023421823 creator A5000403044 @default.
• W2023421823 creator A5001753228 @default.
• W2023421823 creator A5006566781 @default.
• W2023421823 creator A5018459050 @default.
• W2023421823 creator A5023799961 @default.
• W2023421823 creator A5026031446 @default.
• W2023421823 creator A5027207191 @default.
• W2023421823 creator A5039005518 @default.
• W2023421823 creator A5061992932 @default.
• W2023421823 creator A5074975962 @default.
• W2023421823 creator A5075327765 @default.
• W2023421823 creator A5082650086 @default.
• W2023421823 creator A5084436263 @default.
• W2023421823 creator A5085099952 @default.
• W2023421823 date "1998-07-01" @default.
• W2023421823 modified "2023-10-06" @default.
• W2023421823 title "Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate" @default.
• W2023421823 cites W1766338896 @default.
• W2023421823 cites W1969342943 @default.
• W2023421823 cites W1976128207 @default.
• W2023421823 cites W1997219526 @default.
• W2023421823 cites W1998649026 @default.
• W2023421823 cites W2071045101 @default.
• W2023421823 cites W2089447045 @default.
• W2023421823 cites W2116290933 @default.
• W2023421823 cites W2117399653 @default.
• W2023421823 cites W2155539927 @default.
• W2023421823 cites W2162498121 @default.
• W2023421823 cites W2278216800 @default.
• W2023421823 cites W2295538098 @default.
• W2023421823 cites W2415612398 @default.
• W2023421823 cites W2421707424 @default.
• W2023421823 cites W2433788966 @default.
• W2023421823 cites W2471857435 @default.
• W2023421823 cites W2617245288 @default.
• W2023421823 cites W4239330499 @default.
• W2023421823 doi "https://doi.org/10.1016/s0090-4295(98)00129-0" @default.
• W2023421823 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9671874" @default.
• W2023421823 hasPublicationYear "1998" @default.
• W2023421823 type Work @default.
• W2023421823 sameAs 2023421823 @default.
• W2023421823 citedByCount "51" @default.
• W2023421823 countsByYear W20234218232012 @default.
• W2023421823 countsByYear W20234218232014 @default.
• W2023421823 countsByYear W20234218232015 @default.
• W2023421823 countsByYear W20234218232016 @default.
• W2023421823 countsByYear W20234218232017 @default.
• W2023421823 countsByYear W20234218232018 @default.
• W2023421823 crossrefType "journal-article" @default.
• W2023421823 hasAuthorship W2023421823A5000403044 @default.
• W2023421823 hasAuthorship W2023421823A5001753228 @default.
• W2023421823 hasAuthorship W2023421823A5006566781 @default.
• W2023421823 hasAuthorship W2023421823A5018459050 @default.
• W2023421823 hasAuthorship W2023421823A5023799961 @default.
• W2023421823 hasAuthorship W2023421823A5026031446 @default.
• W2023421823 hasAuthorship W2023421823A5027207191 @default.
• W2023421823 hasAuthorship W2023421823A5039005518 @default.
• W2023421823 hasAuthorship W2023421823A5061992932 @default.
• W2023421823 hasAuthorship W2023421823A5074975962 @default.
• W2023421823 hasAuthorship W2023421823A5075327765 @default.
• W2023421823 hasAuthorship W2023421823A5082650086 @default.
• W2023421823 hasAuthorship W2023421823A5084436263 @default.
• W2023421823 hasAuthorship W2023421823A5085099952 @default.
• W2023421823 hasConcept C121608353 @default.
• W2023421823 hasConcept C126322002 @default.
• W2023421823 hasConcept C126894567 @default.
• W2023421823 hasConcept C143998085 @default.
• W2023421823 hasConcept C207103383 @default.
• W2023421823 hasConcept C2776306840 @default.
• W2023421823 hasConcept C2777155358 @default.
• W2023421823 hasConcept C2777911890 @default.
• W2023421823 hasConcept C2779322244 @default.
• W2023421823 hasConcept C2780192828 @default.
• W2023421823 hasConcept C44249647 @default.
• W2023421823 hasConcept C71315377 @default.
• W2023421823 hasConcept C71924100 @default.
• W2023421823 hasConcept C90924648 @default.
• W2023421823 hasConceptScore W2023421823C121608353 @default.
• W2023421823 hasConceptScore W2023421823C126322002 @default.
• W2023421823 hasConceptScore W2023421823C126894567 @default.
• W2023421823 hasConceptScore W2023421823C143998085 @default.
• W2023421823 hasConceptScore W2023421823C207103383 @default.
• W2023421823 hasConceptScore W2023421823C2776306840 @default.
• W2023421823 hasConceptScore W2023421823C2777155358 @default.
• W2023421823 hasConceptScore W2023421823C2777911890 @default.
• W2023421823 hasConceptScore W2023421823C2779322244 @default.
• W2023421823 hasConceptScore W2023421823C2780192828 @default.
• W2023421823 hasConceptScore W2023421823C44249647 @default.
• W2023421823 hasConceptScore W2023421823C71315377 @default.
• W2023421823 hasConceptScore W2023421823C71924100 @default.
• W2023421823 hasConceptScore W2023421823C90924648 @default.
• W2023421823 hasIssue "1" @default.
• W2023421823 hasLocation W20234218231 @default.
• W2023421823 hasLocation W20234218232 @default.
• W2023421823 hasOpenAccess W2023421823 @default.
• W2023421823 hasPrimaryLocation W20234218231 @default.

• next